← Every product built on public research
Lantheus · Piflufolastat F-18
Pylarify: patented from NIH-funded research
–
Medicare paid, 2025
before rebates
–
Medicare, 2020–2025
–
Medicare, 2026 Q1
the newest quarter CMS has published
$15M
NIH grants behind the patents
whole-grant totals, not the drug's cost
The public record, link by link
1 · Public research
6 NIH grants to Ut Southwestern Medical Center, Johns Hopkins University, $15M in all.2 · Patent
8778305, 9861713, 10947197, 11851407, 12070513, reported to NIH under R01CA134675, R21CA111982, R21CA114111, R24CA092871, U01CA183031, U24CA092871.3 · FDA approval
Approved May 26, 2021, sold by Lantheus (NDA 214793).4 · Public pays
Medicaid paid $8.0M in 2024. Medicare's 2025 drug files do not list it.
The grants
Enhanced imaging and treatment of aggressive subtypes of prostate cancer
R01CA134675 · Ut Southwestern Medical Center · NCI · 2009–2025
$6.2M
Interdisciplinary Small Animal Imaging for Oncology
R24CA092871 · Johns Hopkins University · NCI · 2001–2006
$5.1M
Small Animal Imaging Resource (SAIR)
U24CA092871 · Johns Hopkins University · NCI · 2007–2011
$2.3M
PSMA Directed Imaging of Prostate Cancer Focus on Androgen Receptor Dynamics
U01CA183031 · Johns Hopkins University · NCI · 2015–2017
$1.2M
PSMA-based SPECT Tracers for Prostate Cancer Imaging
R21CA114111 · Johns Hopkins University · NCI · 2006–2007
$337K
PSMA-based PET Ligands for Prostate Cancer Imaging
R21CA111982 · Johns Hopkins University · NCI · 2006–2007
$337K
The patents
- FDA-listed expiry Sep 21, 2030
- FDA-listed expiry Jul 31, 2029
- US 10947197FDA-listed expiry Jun 9, 2037
An improved synthesis of the radiolabeled PSMA inhibitor, [18F] DCFPyL
Reported by Johns Hopkins University
- US 11851407FDA-listed expiry Jun 9, 2037
SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPYL
Reported by Johns Hopkins University
- FDA-listed expiry Jul 31, 2029
Lantheus's side
Drug makers pay for the clinical trials that take a compound from the lab to FDA approval, and they pay royalties on licensed patents. Those terms are not public. Separately, Lantheus received $7.0M in federal contracts and grants since fiscal 2020, which includes purchases. Lantheus's page shows its other products on this list, its federal awards, its PAC's giving and its lobbying. If Lantheus wants to add its account, we will publish it here.
How this is built. A product is listed for one of two public records. Either NIH's Technology Transfer office lists it as an FDA-approved product built on a license from an NIH, CDC or FDA lab, or a patent the FDA lists for the drug was reported to NIH as an invention made with NIH grant money, as the Bayh-Dole Act requires. We then add what Medicare Part D, Part B and Medicaid paid for each product, and for each company, the federal grants and contracts it received, its PAC's donations and its lobbying.
What the numbers mean. Medicare and Medicaid figures are gross spending before the rebates drug makers pay back, which are confidential. Hospital-administered therapies such as CAR-T cell treatments are mostly paid under Medicare Part A and do not appear in these files. "NIH grants" is everything NIH paid on the grants a patent was reported under, from 1985 on; a grant usually paid for more than one invention, so it is not the cost of the drug. Federal contracts include purchases, such as vaccine doses, as well as research. Companies also paid for the clinical trials that took these products to approval. None of these figures shows that public money set a price or bought a decision.
Sources: NIH Technology Transfer: FDA-approved products licensed from NIH, CDC and FDA labs; NIH RePORTER patents reported under NIH grants (from iEdison); NIH RePORTER project funding; FDA Orange Book patent, exclusivity and product files; CMS Medicare Part D and Part B Spending by Drug (annual and quarterly); CMS Medicaid Spending by Drug; USAspending.gov federal grants and contracts. Updated 2026-11-06.